1. Pfizer-BioNTech’s three-dose vaccine for children 6 months to 4 years old prevented symptomatic disease in clinical trials, according to The Wall Street Journal.
In a study data review by the FDA, U.S. health regulators found the risk of adverse effects were comparable to older age groups, according to the Journal.
2. The FDA deemed Moderna’s vaccine “safe and effective” for 6-month-old to 5-year-old children, the Washington Post reported.
Moderna’s two-dose vaccine candidate promoted lower adverse reactions compared to children in other age groups, with the exception of fever, which affected 21 percent to 26 percent of children after either dose, according to the agency’s report.
The FDA will meet June 15 to discuss each vaccine’s results.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
